Suppr超能文献

蛋白 S 遗传性质量缺陷:新型突变及表型影响。

Protein S inherited qualitative deficiency: novel mutations and phenotypic influence.

机构信息

Hématologie biologique, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.

出版信息

J Thromb Haemost. 2010 Dec;8(12):2718-26. doi: 10.1111/j.1538-7836.2010.04073.x.

Abstract

BACKGROUND

Only a few mutations associated with qualitative protein S deficiency have already been described. Sensitivity and specificity for type II PROS1 mutations of commercially available reagents for measuring Protein S (PS) activity are not well established. Whether these mutations are significant risk factors for thrombosis remains an unresolved question.

METHODS

In order to address the first point, we present and discuss the results of PROS1 analysis performed in the 30 probands with type II PS-inherited deficiency suspicion and 35 relatives, studied in our laboratory between 2000 and 2008. In order to investigate the influence of type II mutations on the coagulability level, thrombin generation tests were performed on plasma from 102 PROS1 type II, type I/III or PS Herleen mutation heterozygous carriers and controls.

RESULTS

Mutations (12 novel, six already described) which probably explain the qualitative phenotype, were found in 27 (90%) out of the 30 probands studied. In relatives, 78% of heterozygotes presented with a type II phenotype. An APC resistance phenotype was documented in type II and type I/III defects heterozygous carriers; however, the effect of type II was milder than the effect of type I/III PS mutations.

CONCLUSIONS

A PS functional assay (Staclot PS, Stago) was efficient in screening for PROS1 type II defects, particularly in probands. A significant positive influence of type II mutations on ex vivo thrombin generation was demonstrated. However, whether these mutations increase the risk of venous thromboembolism requires further investigation.

摘要

背景

仅有少数与定性蛋白 S 缺乏相关的突变已被描述。目前,市售用于测量蛋白 S(PS)活性的试剂检测 PROS1 类型 II 突变的灵敏度和特异性尚未得到很好的确定。这些突变是否是血栓形成的重要危险因素仍然是一个悬而未决的问题。

方法

为了解决第一个问题,我们介绍并讨论了在 2000 年至 2008 年期间在我们实验室研究的 30 名疑似 II 型 PS 遗传性缺陷的先证者和 35 名亲属中进行的 PROS1 分析结果。为了研究 II 型突变对凝血水平的影响,对 102 名 PROS1 类型 II、I/III 或 PS Herleen 突变杂合子携带者和对照者的血浆进行了凝血酶生成试验。

结果

在研究的 30 名先证者中,发现了 27 名(90%)可能解释定性表型的突变(12 个新突变,6 个已描述的突变)。在亲属中,78%的杂合子表现为 II 型表型。在 II 型和 I/III 缺陷杂合子携带者中发现 APC 抵抗表型;然而,II 型的作用比 I/III PS 突变的作用更温和。

结论

PS 功能测定(Staclot PS,Stago)在筛选 PROS1 类型 II 缺陷方面非常有效,特别是在先证者中。证明 II 型突变对体外凝血酶生成有显著的正向影响。然而,这些突变是否增加静脉血栓栓塞的风险还需要进一步研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验